Haisco Pharmaceutical Group Co., Ltd. (002653.SZ)
CNY 42.8
(-0.23%)
CNY 42.8
(-0.23%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 854.68 Million CNY | -35.05% |
| 2022 | 1.31 Billion CNY | 184.03% |
| 2021 | 463.31 Million CNY | 38.34% |
| 2020 | 334.9 Million CNY | 319.15% |
| 2019 | 79.9 Million CNY | -68.67% |
| 2018 | 255 Million CNY | 385.82% |
| 2017 | 52.48 Million CNY | -74.0% |
| 2016 | 201.91 Million CNY | 521.87% |
| 2015 | 32.46 Million CNY | 0.0% |
| 2014 | - CNY | 0.0% |
| 2013 | - CNY | 0.0% |
| 2012 | - CNY | -100.0% |
| 2011 | 450.45 Thousand CNY | -97.86% |
| 2010 | 21.06 Million CNY | 0.0% |
| 2009 | - CNY | -100.0% |
| 2008 | 6.3 Million CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 1.16 Billion CNY | 36.26% |
| 2024 Q1 | 937.93 Million CNY | 9.74% |
| 2024 Q2 | 854.27 Million CNY | -8.92% |
| 2023 Q1 | 955.44 Million CNY | -27.4% |
| 2023 FY | 854.68 Million CNY | -35.05% |
| 2023 Q4 | 854.68 Million CNY | 17.75% |
| 2023 Q3 | 725.86 Million CNY | -9.17% |
| 2023 Q2 | 799.17 Million CNY | -16.36% |
| 2022 FY | 1.31 Billion CNY | 184.03% |
| 2022 Q4 | 1.31 Billion CNY | 13.14% |
| 2022 Q3 | 1.16 Billion CNY | -5.77% |
| 2022 Q2 | 1.23 Billion CNY | 61.93% |
| 2022 Q1 | 762.26 Million CNY | 64.53% |
| 2021 Q3 | 446.79 Million CNY | -11.84% |
| 2021 Q2 | 506.8 Million CNY | -10.38% |
| 2021 FY | 463.31 Million CNY | 38.34% |
| 2021 Q1 | 565.5 Million CNY | 68.86% |
| 2021 Q4 | 463.31 Million CNY | 3.7% |
| 2020 Q1 | 124.95 Million CNY | 56.38% |
| 2020 Q2 | 314.9 Million CNY | 152.02% |
| 2020 Q3 | 314.9 Million CNY | 0.0% |
| 2020 Q4 | 334.9 Million CNY | 6.35% |
| 2020 FY | 334.9 Million CNY | 319.15% |
| 2019 Q1 | 260 Million CNY | 1.96% |
| 2019 Q3 | 30 Million CNY | -66.67% |
| 2019 Q4 | 79.9 Million CNY | 166.33% |
| 2019 FY | 79.9 Million CNY | -68.67% |
| 2019 Q2 | 90 Million CNY | -65.38% |
| 2018 FY | 255 Million CNY | 385.82% |
| 2018 Q1 | 90 Million CNY | 73.75% |
| 2018 Q2 | 270 Million CNY | 200.0% |
| 2018 Q3 | 265 Million CNY | -1.85% |
| 2018 Q4 | 255 Million CNY | -3.77% |
| 2017 Q4 | 51.79 Million CNY | 86901645325107300.0% |
| 2017 FY | 52.48 Million CNY | -74.0% |
| 2017 Q3 | - CNY | -100.0% |
| 2017 Q2 | 30.48 Million CNY | -84.84% |
| 2017 Q1 | 201.04 Million CNY | -0.43% |
| 2016 Q2 | 231.16 Million CNY | 661.23% |
| 2016 FY | 201.91 Million CNY | 521.87% |
| 2016 Q1 | 30.36 Million CNY | -6.47% |
| 2016 Q4 | 201.91 Million CNY | -12.49% |
| 2016 Q3 | 230.71 Million CNY | -0.19% |
| 2015 Q2 | - CNY | 0.0% |
| 2015 FY | 32.46 Million CNY | 0.0% |
| 2015 Q4 | 32.46 Million CNY | 2.08% |
| 2015 Q3 | 31.8 Million CNY | 0.0% |
| 2015 Q1 | - CNY | 0.0% |
| 2014 FY | - CNY | 0.0% |
| 2014 Q3 | - CNY | 0.0% |
| 2014 Q2 | - CNY | 0.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 Q4 | - CNY | 0.0% |
| 2013 Q3 | - CNY | 0.0% |
| 2013 FY | - CNY | 0.0% |
| 2013 Q4 | - CNY | 0.0% |
| 2013 Q1 | - CNY | 0.0% |
| 2013 Q2 | - CNY | 0.0% |
| 2012 Q2 | 450.45 Thousand CNY | 53.75% |
| 2012 Q3 | 450.45 Thousand CNY | 0.0% |
| 2012 Q4 | - CNY | -100.0% |
| 2012 FY | - CNY | -100.0% |
| 2012 Q1 | 292.98 Thousand CNY | -34.96% |
| 2011 FY | 450.45 Thousand CNY | -97.86% |
| 2011 Q2 | 20.83 Million CNY | 0.0% |
| 2011 Q3 | 678.98 Thousand CNY | -96.74% |
| 2011 Q4 | 450.45 Thousand CNY | -33.66% |
| 2010 FY | 21.06 Million CNY | 0.0% |
| 2010 Q4 | 21.06 Million CNY | 0.0% |
| 2009 FY | - CNY | -100.0% |
| 2008 FY | 6.3 Million CNY | 0.0% |